Stable coronary artery disease: focus on the plaque and hypertriglyceridemia
DOI:
https://doi.org/10.34687/2219-8202.JAD.2023.04.0002Keywords:
coronary artery disease, triglycerides, high risk plaque, omega-3 free fatty acidsAbstract
This work deals with new data concerning the pathogenesis of coronary heart disease. Fundamental works and clinical studies report no direct relationships between the severity of coronary artery lesions and the risk of adverse cardiovascular events. Currently more attention is focused on the total extension of atherosclerotic process within coronary arteries as well as morphological features of the plaques. The modern concept of coronary artery disease is constantly moving from the theory of ischemia and lesion severity as key prognostic determinants to morphological and biological changes occuring inside the atherosclerotic plaque which are responsible of the plaque destabilisation and occurrence of acute events. Up to date visualisation modalities capable to distinguish stable and unstable plaques based on their morphological features and to exactly describe high risk plaque. According to the modern total cardiovascular risk concept the patient suffering cardiovascular disease should be treated to achieve target levels of total cholesterol, low density lipoproteid cholesterol, blood pressure, glycaemic profile and other risk factors. But achievement of this target levels doesn’t eliminate the risk completely, residual risk is comprised of prothrombotic factors, systemic inflammation process, lipoproteid (a) and triglycerides levels. The purpose of this work is to analyse relationships between elevated triglycerides levels and atherogenesis including the formation of high risk plaques as well as to overview current pharmacological treatment modalities using omega-3 free fatty acids drugs.
Downloads
References
Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation. 2012;125(9):1147-1156. doi:10.1161/CIRCULATIONAHA.111.047431.
Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, et al. PCI and CABG for Treating Stable Coronary Artery Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(8):964-976. doi: 10.1016/j.jacc.2018.11.053.
Arbab-Zadeh A, Fuster V. The Risk Continuum of Atherosclerosis and its Implications for Defining CHD by Coronary Angiography. J Am Coll Cardiol. 2016;68(22):2467-2478. doi:10.1016/j.jacc.2016.08.069.
Pijls NH. Acute myocardial infarction and underlying stenosis severity. Am J Cardiol. 2009;(103):1204–5. doi: 10.1016/j.amjcard.2009.01.027.
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 12(356):1503-16. doi: 10.1056/NEJMoa070829.
Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A ran-domized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360(24):2503-2515. doi: 10.1056/NEJMoa0805796.
Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, et al. IS-CHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-1407. doi: 10.1056/NEJMoa1915922.
Kedhi E, Berta B, Roleder T, Hermanides RS, Fabris E, IJsselmuiden AJJ, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow re-serve: the COMBINE OCT-FFR trial. Eur Heart J. 2021;42(45):4671-4679. doi: 10.1093/eurheartj/ehab433.
Nerlekar N, Ha FJ, Cheshire C, Rashid H, Cameron JD, Wong DT, et al. Computed Tomo-graphic Coronary Angiography-Derived Plaque Characteristics Predict Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Circ Cardiovasc Imag-ing. 2018;11(1):e006973. doi:10.1161/CIRCIMAGING.117.006973.
Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysi-ology. Nat Clin Pract Cardiovasc Med. 2009;6(1):16-26. doi:10.1038/ncpcardio1397.
Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study. Eur Heart J. 2015;36(36):2446-2453. doi:10.1093/eurheartj/ehv251.
Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol. J Clin Endo-crinol Metab. 2018;103(8):3019-3027. doi:10.1210/jc.2018-00470.
Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet Need for Adjunc-tive Dyslipidemia Therapy in Hypertriglyceridemia Management. J Am Coll Cardiol. 2018;72(3):330-343. doi:10.1016/j.jacc.2018.04.061.
Borén J, Packard CJ, Taskinen MR. The Roles of ApoC-III on the Metabolism of Triglycer-ide-Rich Lipoproteins in Humans. Front Endocrinol (Lausanne). 2020;28(11):474. doi: 10.3389/fendo.2020.00474.
Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia. 2000; 43:703–8. doi: 10.1007/s0012500 51366
Packard CJ, Boren J, Taskinen M-R. Causes and Consequences of Hypertriglyceridemia. Front. Endocrinol. 2020; 11:252. doi: 10.3389/fendo.2020.00252.
Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384(9943):626-635. doi: 10.1016/S0140-6736(14)61177-6.
Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular dis-ease: new insights from epidemiology, genetics, and biology. Circ Res. 2016; 118(4):547–63. doi: 10.1161/CIRCRESAHA.115.306249.
Рекомендации Российского кардиологического общества по нарушениям липидного обмена, 2023 год. https://scardio.ru/content/Guidelines/2023/Clinic_rekom_HSN-unlocked.pdf. Доступны 06.07.2023.
Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClini-calMedicine. 2021; 8(38):100997. doi: 10.1016/j.eclinm.2021.100997.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglycer-idemia. N Engl J Med. 2019;380(1):11-22. doi: 10.1056/NEJMoa1812792.
Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R et al. Gissi-HF In-vestigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223-30. doi: 10.1016/S0140-6736(08)61239-8.
Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A, et al. Effects of n-3 poly-unsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. Am Heart J. 2011;161(2):338-343. doi: 10.1016/j.ahj.2010.10.032.
Dimitrow PP, Jawien M. Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Mini Rev Med Chem. 2009;9(9):1030-9. doi:10.2174/138955709788922638.
Cho I, Al'Aref SJ, Berger A, Ó Hartaigh B, Gransar H, Valenti V, et al. Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study. Eur Heart J. 2018;39(11):934-941. doi: 10.1093/eurheartj/ehx774.
Nerlekar N, Ha FJ, Cheshire C, Rashid H, Cameron JD, Wong DT, еt al. Computed Tomo-graphic Coronary Angiography-Derived Plaque Characteristics Predict Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Circ Cardiovasc Imag-ing. 2018;11(1):e006973. doi: 10.1161/CIRCIMAGING.117.006973.
Nelson JR, Wani O, May HT, Budoff M. Potential benefits of eicosapentaenoic acid on ath-erosclerotic plaques. Vascul Pharmacol. 2017;91:1-9. doi: 10.1016/j.vph.2017.02.004.
Watanabe T, Ando K, Daidoji H, Otaki Y, Sugawara S, Matsui M, et al.; CHERRY study in-vestigators. A randomized controlled trial of eicosapentaenoic acid in patients with coro-nary heart disease on statins. J Cardiol. 2017;70(6):537-544. doi: 10.1016/j.jjcc.2017.07.007.
Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated tri-glycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925-3932. doi: 10.1093/eurheartj/ehaa652.
Рекомендации Российского кардиологического общества по лечению хронической сердечной недостаточности, 2020 год. https://scardio.ru/content/Guidelines/2020/Clinic_rekom_HSN-unlocked.pdf. Доступны 06.07.2023.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Commit-tee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e894. doi: 10.1161/CIR.0000000000001062.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
State Register of Medicines. Registration certificate of the drug Omacor. Av. at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=9f089875-e660-4bbf-ae28- d03332634a18. [Russian: Государственный реестр лекарственных средств. Регистрационное удостоверение препарата Омакор. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9f089875-e660-4bbf-ae28-d03332634a18]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 А. В. Панов, В. Ю. Козулин, Ю. А. Кудаев
This work is licensed under a Creative Commons Attribution 4.0 International License.